Stockscreener 앱 받기
10.75
1.19%
-0.13
시간 외 거래:
10.66
-0.09
-0.84%
전일 마감가:
$10.88
열려 있는:
$10.85
하루 거래량:
3.22M
Relative Volume:
0.73
시가총액:
$2.25B
수익:
$503.49M
순이익/손실:
$-53.47M
주가수익비율:
-41.35
EPS:
-0.26
순현금흐름:
$-26.89M
1주 성능:
+1.51%
1개월 성능:
+27.37%
6개월 성능:
+43.33%
1년 성능:
+63.62%
1일 변동 폭
$10.62
$10.88
1주일 범위
$10.46
$11.03
52주 변동 폭
$5.92
$11.11
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
10.75 | 2.22B | 503.49M | -53.47M | -26.89M | -0.26 |
|
HLN
Haleon Plc Adr
|
11.35 | 50.14B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
168.63 | 72.38B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.79 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.51B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.45B | 16.54B | -1.64B | 749.00M | -1.45 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
BioCryst (BCRX) Highlights Positive Data on Berotralstat for HAE Treatment | BCRX Stock News - GuruFocus
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotrals - GuruFocus
BioCryst reports efficacy of HAE drug across age groups - Investing.com
BioCryst Highlights Real-world Data Showing ORLADEYO® - GlobeNewswire
BCRXBiocryst Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Drugmaker targets younger patients as revenue balloons - The Business Journals
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
BioCryst to Present at Upcoming Investor Conferences | BCRX Stock News - GuruFocus
BioCryst to Present at Upcoming Investor Conferences - The Manila Times
How To Trade (BCRX) - news.stocktradersdaily.com
Bank of America Corp DE Sells 261,127 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade - Yahoo Finance
BioCryst Pharmaceuticals Inc (BCRX) Trading 3.62% Higher on May 22 - GuruFocus
Orladeyo reduces swelling rates in severe HAE: Real-world data - Angioedema News
BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded by StockNews.com to Strong-Buy Rating - Defense World
Transcript : BioCryst Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 03 - marketscreener.com
D. E. Shaw & Co. Inc. Increases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst's Orladeyo up for FDA review in pediatric HAE patients - MSN
BioCryst Pharmaceuticals’ SWOT analysis: stock outlook amid Orladeyo success, pipeline progress - Investing.com Nigeria
BNP Paribas Financial Markets Trims Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Ameriprise Financial Inc. Sells 51,920 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Best Momentum Stocks to Buy for May 9th - The Globe and Mail
BioCryst reports ORLADEYO reduces severe HAE attack rates By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals (NASDAQ:BCRX) Cut to Buy at StockNews.com - Defense World
(BCRX) Long Term Investment Analysis - news.stocktradersdaily.com
BioCryst reports ORLADEYO reduces severe HAE attack rates - Investing.com Australia
BioCryst Presents New Real-world Evidence Showing Significant an - GuruFocus
BioCryst (BCRX) Highlights Significant HAE Attack Reductions with ORLADEYO | BCRX Stock News - GuruFocus
BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat) - GlobeNewswire
New Clinical Evidence: ORLADEYO Dramatically Reduces HAE Attacks in Both Teens and Severe Patients - Stock Titan
FDA to review Orladeyo application for young children with HAE - Angioedema News
FDA awards BioCryst’s Orladeyo NDA for paediatric HAE - Yahoo
The Manufacturers Life Insurance Company Sells 195,621 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst (BCRX) Gains FDA Priority Review for Pediatric ORLADEYO - GuruFocus
Clearside's Wet AMD Drug Advances to Phase 3: FDA Green Light Could Transform Eye Disease Treatment - Stock Titan
FDA accepts NDA for berotralstat in HAE patients aged 2 to 11 years - Contemporary Pediatrics
INZ-701 shows early promise in treating ENPP1 Deficiency in pediatric patients - Contemporary Pediatrics
BioCryst’s ORLADEYO Receives FDA Priority Review - TipRanks
Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 Years - marketscreener.com
BioCryst Announces FDA Acceptance of NDA for ORLADEYO® - GlobeNewswire
FDA Fast-Tracks First-Ever Oral HAE Treatment for Children Under 12: September Decision Expected - Stock Titan
BioCryst targets $1B in global ORLADEYO revenue by 2029 amid 33-37% projected growth this year - MSN
BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $11.00 - Defense World
Best Momentum Stocks To Buy For May 9th - Barchart.com
New Strong Buy Stocks for May 9th - The Globe and Mail
Mariner LLC Buys 3,224 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Transcript : BioCryst Pharmaceuticals, Inc. Presents at The Citizens JMP Life Sciences Conference 2025, May-08-2025 09 - marketscreener.com
Why BioCryst (BCRX) Might be Well Poised for a Surge - Yahoo Finance
What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
BioCryst at Citizens JMP: Orlodayo’s Market Growth and Pipeline Prospects - Investing.com
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
18.36%
0.52%
자본화:
|
볼륨(24시간):